COGT News and Press, Cogent Biosciences Inc Com From 04/11/22

New bezuclastinib nonclinical data demonstrate superior selectivity against closely related kinases, as well as minimal brain penetration, compared with other KIT inhibitors Building a pipeline of multiple small molecule inhibitors targeting genetically defined diseases, includi...

CAMBRIDGE, Mass. and BOULDER, Colo., March 29, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced details for its planned Virtual R&D In...

Cogent Biosciences press release (NASDAQ:COGT): Q4 Net Loss of $24.9M As of December 31, 2021, the company had cash and cash equivalents of $219.7 million. For further details see: Cogent Biosciences reports Q4 results

APEX, SUMMIT and PEAK bezuclastinib clinical trials actively enrolling patients APEX initial clinical data presentation expected in the first half of 2022 R&D Investor Event planned for April 8, 2022 Ended 2021 with $219.7 million in cash, sufficient to fund ...

CAMBRIDGE, Mass. and BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the publication of two abstracts for its upcoming po...

Cogent Biosciences Provides 2022 Corporate Guidance APEX, SUMMIT and PEAK bezuclastinib clinical trials all initiated and enrolling APEX preliminary clinical data readout expected in the first half of 2022 R&D investor event planned April 2022 to detail robust discov...

Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference PR Newswire CAMBRIDGE, Mass. and BOULDER, Colo. , Nov. 22, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developin...

Cogent Biosciences (NASDAQ:COGT): Q3 Net Loss of $19.1M Cash and cash equivalents of $202.9M Press Release For further details see: Cogent Biosciences reports Q3 results

Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results Initiated SUMMIT, a Phase 2 clinical trial of bezuclastinib for Nonadvanced Systemic Mastocytosis (NonAdvSM) patients PEAK, a Phase 3 clinical trial of bezuclastinib and sunitinib ...

Cogent Biosciences to Present Virtually at Jefferies London Healthcare Conference 2021 PR Newswire CAMBRIDGE, Mass. and BOULDER, Colo. , Nov. 2, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on dev...